Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib

Published:2014-08 Issue:2 Volume:61 Page:318-324
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Reig Maria,Torres Ferran,Rodriguez-Lope Carlos,Forner Alejandro,LLarch Neus,Rimola Jordi,Darnell Anna,Ríos José,Ayuso Carmen,Bruix Jordi

Funder

Instituto de Salud Carlos III

University of Barcelona

Publisher

Elsevier BV

Subject

Hepatology

Reference29 articles.

1. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

2. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial;Bruix;J Hepatol,2012

3. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma;Llovet;Clin Cancer Res,2012

4. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib;Vincenzi;Oncologist,2010

5. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib;Otsuka;Hepatol Res,2012

Cited by 207 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heterogeneity in adverse events related to Atezolizumab-Bevacizumab for hepatocellular carcinoma reported in real-life studies;JHEP Reports;2024-08

2. Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials;Clinical Pharmacology & Therapeutics;2024-05-27

3. Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review);International Journal of Oncology;2024-05-09

4. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab;Targeted Oncology;2024-04-30

5. Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma;Cancers;2024-04-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3